TD Cowen Sets $51 Target on Wayfair

TD Cowen initiated coverage on Wayfair (NYSE: W) in early June, giving the stock a Buy rating and a price target of $51, given its leadership in healthcare software.

Analysts describe Wayfair as a key player in SaaS tools for healthcare providers. That includes managing billing cycles, handling patient payments, and clearinghouse services, systems that keep the financial engine running behind the scenes.

TD Cowen pointed to structural tailwinds: rising complexity in medical billing and a growing chunk of patient costs shifting out-of-pocket. These trends, they argue, give Wayfair room to grow as providers turn to software to keep up.

A clinical medical professional helping a patient while using an integrated health information technology software.

It’s not the kind of bullish case that leans on hype or flashy growth figures. It’s more about fundamentals, sticky software in a sector that can’t afford to fall behind.

With that setup, TD Cowen sees a path for steady growth, and their $51 target reflects confidence in Wayfair’s ability to scale as the healthcare system keeps getting messier.

While we acknowledge the potential of W as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.